mRNA cancer vaccines are one of the more visible investigational directions in melanoma. Personalized vaccines such as V940/mRNA-4157 are designed from mutationsA change in DNA sequence that can drive cancer development.Click for full explanation → found in a person's tumor and are being tested with pembrolizumab after surgery for high-risk melanoma. The goal is to lower the chance of recurrence, but this remains trial-stage treatment rather than standard care. Phase 3 trials are extending immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → combinations and cellular therapies. Fianlimab (anti-LAG-3) combined with cemiplimab (anti-PD-1) is being tested against pembrolizumab in untreated unresectable or metastatic melanoma. SUPRAME compares the engineered T-cell receptor therapy IMA203 against several investigator's choice options in previously treated cutaneous melanoma. A Phase 4 ctDNA-guided trial tests addition of ipilimumab to nivolumab and relatlimab based on circulating tumor DNA. Phase 3 work is also assessing intermittent versus continuous PD-1 therapy in metastatic disease. Earlier studies include TIL therapies engineered with membrane-bound IL-15, PRAME-targeted T-cell receptor NK cells, novel RNA lipid particle vaccines, oncolytic and bispecific approaches such as REGN10597 with cemiplimab, and the combination of fianlimab, cemiplimab, and ipilimumab. For mucosal melanoma, an underserved subtype, adjuvant short-course radiotherapy plus chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → and a PD-1 inhibitor is being tested. Laboratory work has identified BET inhibitors as immunogenicity boosters, KLRG1 as a new checkpoint target, mechanisms of drug-tolerant persister cell formation, and immune signatures that predict non-response to PD-1 therapy.
Where the evidence stands
Single-agent and combination immune checkpoint blockade and BRAF and MEK inhibition are firmly established with overall survivalThe percentage of patients still alive after a set period — a key clinical trial endpoint.Click for full explanation → benefits and have changed long-term outcomes in advanced melanoma. TIL therapy with lifileucel is now an approved option for refractory disease, the first cellular therapy in a solid tumor. The next wave, anti-LAG-3 combinations, engineered T-cell receptor cell therapies, and radioligand or bispecific approaches, is in late Phase 3. Mucosal and uveal melanoma remain harder to treat, with targeted approaches in earlier development.
What this means for people affected
Cutaneous melanoma has seen one of the most dramatic survival improvements in oncology over the past 15 years, with long-term survival now possible in metastatic disease for many people receiving immune checkpoint blockade. BRAF mutationA change in DNA sequence that can drive cancer development.Click for full explanation → testing is standard at diagnosis of advanced disease and shapes targeted therapyDrugs that block specific molecules that cancer cells need to grow.Click for full explanation → decisions. Resistance to immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → is the central remaining challenge, and several trials, including TIL therapies, anti-LAG-3 combinations, and engineered cell therapies, address this. Mucosal and uveal melanoma have fewer options and generally warrant clinical trialA research study that tests a medical intervention in human volunteers.Click for full explanation → consideration. Adjuvant and neoadjuvant immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → approaches for resectable disease are also active areas of research.
Last updated May 22, 2026
Recent research findings
Understanding evidence levels▼
PreclinicalLab or cell studies — no human data yet.
Animal StudyResults in animals only — may not apply to humans.
Phase 1 TrialFirst-in-human safety testing in small groups.
Phase 2 TrialEarly effectiveness testing in a larger group.
Phase 3 TrialLarge controlled trial — the strongest trial evidence.
Observational StudyPatterns observed in populations — not a controlled trial.
ReviewSummary analysis of multiple existing studies.
Meta-AnalysisStatistical pooling of results from multiple studies.
PreclinicalLab or cell studies. No human data yet.Est. completion: September 30, 2033
Timing of ImmunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → in Melanoma Treatment
This clinical trialA research study that tests a medical intervention in human volunteers.Click for full explanation → is studying the timing of immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → in patients with melanoma. Researchers want to know if administering immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → at different times of the day affects treatment outcomes. The trial is currently recruiting participants.
Why it matters: Understanding the optimal timing of immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → may help improve treatment for melanoma patients.
Phase 1 TrialFirst-in-human trial. Focuses on safety and dosing in small groups.Est. completion: May 4, 2028
Testing MQ719 with and without Pembrolizumab in Solid Tumor Cancer Patients
This clinical trialA research study that tests a medical intervention in human volunteers.Click for full explanation → is studying the safety and effectiveness of MQ719, with and without the medication Pembrolizumab, in people with various types of solid tumor cancer. The trial is currently recruiting participants. The results of this trial are not yet available.
Why it matters: This trial may help researchers understand how MQ719 works in combination with Pembrolizumab to treat solid tumor cancer.
This trial is recruiting participants and is in its early stages.
PreclinicalLab or cell studies. No human data yet.Est. completion: June 1, 2029
Exercise and Nutrition Study for Melanoma Patients on ImmunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation →
This trial is studying whether structured exercise and personalized nutrition can help patients with melanoma who are receiving immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation →. The trial is currently recruiting participants. The results of this study are not yet known.
Why it matters: This trial may provide insights into how exercise and nutrition can support patients with melanoma undergoing immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation →.
Phase 2 TrialTests early effectiveness in a larger group after phase 1 safety is established.Est. completion: January 23, 2029
Testing a Special Diet with ImmunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → in Melanoma Patients
This clinical trialA research study that tests a medical intervention in human volunteers.Click for full explanation → is studying the effects of a prebiotic food-enriched diet combined with immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → drugs ipilimumab and nivolumab in patients with melanoma who have not responded to previous immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation →. The trial is currently active but not recruiting participants. The goal is to understand if this combination can help these patients.
Why it matters: This trial may provide insights into new ways to treat melanoma patients who have not responded to standard treatments.
Lab StudyLaboratory experiments on cells or tissue. No human or animal data.Published: August 7, 2026
Melanoma Patients' Immune Cells May Predict Treatment Outcomes
Researchers studied the immune cells of melanoma patients to see if they could predict how well patients would respond to treatment. They found that certain types of immune cells were associated with better or worse outcomes. However, more research is needed to confirm these findings.
Why it matters: This study could help doctors identify which patients are most likely to benefit from certain treatments and which may need alternative approaches.
Observational StudyPatterns observed in populations over time, not a controlled experiment.Published: August 7, 2026
New Study Examines Brain Metastases in Melanoma Patients
Researchers analyzed data from 422 patients with brain metastases to identify factors that predict survival. They found that clinical features were the strongest predictors of risk across all patients, but radiomic features provided better predictions for melanoma patients.
Why it matters: This finding could help doctors better understand and manage brain metastases in melanoma patients.
Efficacy
80% and 67% of melanoma patients were correctly classified into the low- and the high-risk group for OS, respectively.
Phase 2 TrialTests early effectiveness in a larger group after phase 1 safety is established.Est. completion: April 1, 2027
Testing Dabrafenib and Trametinib Before and After Surgery for Advanced Melanoma
This clinical trialA research study that tests a medical intervention in human volunteers.Click for full explanation → is studying the effectiveness of the medications dabrafenib and trametinib in treating patients with stage IIIB-C melanoma who have a specific genetic mutationA change in DNA sequence that can drive cancer development.Click for full explanation →. The trial is currently active but not recruiting participants. The goal is to see if these medications can help patients before and after surgery.
Why it matters: This trial may provide valuable information about the potential benefits of using dabrafenib and trametinib in combination with surgery for patients with advanced melanoma.
Phase 1/2 TrialCombined safety and early effectiveness trial in humans.Est. completion: January 1, 2029
Testing a New ImmunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → for Advanced Solid Tumors
This clinical trialA research study that tests a medical intervention in human volunteers.Click for full explanation → is studying a treatment called KSQ-001EX, which uses a patient's own immune cells to fight cancer. The trial is currently active but not recruiting participants. The goal is to see if this treatment is safe and effective for people with advanced solid tumors.
Why it matters: This trial could provide new insights into the treatment of advanced solid tumors, a type of cancer that is often difficult to manage.
Phase 1 TrialFirst-in-human trial. Focuses on safety and dosing in small groups.Published: August 7, 2026
Melanoma Cells Evade Immune System Through Epigenetic Changes
Researchers studied melanoma patients who received a new type of immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation →. They found that the cancer cells can change their behavior to evade the immune system, and that these changes are linked to the effectiveness of the treatment. The researchers also identified specific genes that may play a role in this process.
Why it matters: This finding could help researchers understand how melanoma cells become resistant to treatment and identify new targets for therapy.
Phase 2 TrialTests early effectiveness in a larger group after phase 1 safety is established.Est. completion: December 31, 2027
Testing Radiation Therapy for Melanoma with Positive Lymph Nodes
This clinical trialA research study that tests a medical intervention in human volunteers.Click for full explanation → is studying the use of radiation therapy for people with melanoma that has spread to their lymph nodes. The trial is currently recruiting participants. The goal is to learn more about the effectiveness of this treatment.
Why it matters: This trial aims to improve treatment options for people with melanoma that has spread to their lymph nodes.
PreclinicalLab or cell studies. No human data yet.Est. completion: March 1, 2027
Studying Uveal Melanoma: A Prospective Natural History Study
This trial is observing people with uveal melanoma to learn more about the disease's progression and characteristics. The study is currently active but not recruiting participants. The goal is to gather information about the disease.
Why it matters: Understanding uveal melanoma's progression can help researchers develop more effective treatments and improve patient outcomes.
The trial is currently not recruiting participants and is in an active status.
PreclinicalLab or cell studies. No human data yet.Est. completion: December 1, 2028
Study Examines Effect of Aggressive Lipid Lowering on Melanoma Patients
This clinical trialA research study that tests a medical intervention in human volunteers.Click for full explanation → is studying the effect of aggressive lipid lowering therapy on melanoma patients who have received immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation →. The trial is currently recruiting participants. The results of this study will help researchers understand if this treatment approach can improve outcomes for these patients.
Why it matters: This trial may provide valuable insights into new treatment options for melanoma patients who have received immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation →.
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma
